[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 10 of about 29
1. Bhatt VR, Koirala B, Terjanian T: Extranodal natural killer/T cell lymphoma, nasal type presenting as a palatal perforation and naso-oral fistula. BMJ Case Rep; 2011;2011
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extranodal natural killer/T cell lymphoma, nasal type presenting as a palatal perforation and naso-oral fistula.
  • Extranodal natural killer/T cell lymphoma (ENKL), nasal type, a rare disease presenting with vague non-specific symptoms, can impose great diagnostic difficulties and may masquerade several infectious, rheumatological or neoplastic conditions.
  • [MeSH-major] Lymphoma, Extranodal NK-T-Cell / complications. Lymphoma, Extranodal NK-T-Cell / diagnosis. Mouth Diseases / etiology. Nose Diseases / etiology. Oral Fistula / etiology. Palate. Respiratory Tract Fistula / etiology
  • [MeSH-minor] Humans. Male. Young Adult

  • MedlinePlus Health Information. consumer health - Mouth Disorders.
  • MedlinePlus Health Information. consumer health - Nose Injuries and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Auris Nasus Larynx. 2006 Mar;33(1):57-61 [16043319.001]
  • [Cites] Indian J Dermatol Venereol Leprol. 2006 May-Jun;72(3):218-21 [16766838.001]
  • [Cites] N Engl J Med. 2007 Nov 8;357(19):1956 [17989388.001]
  • [Cites] Hematol Oncol. 2008 Jun;26(2):66-72 [18283711.001]
  • [Cites] Arthritis Rheum. 2008 Aug;58(8):2564 [18668555.001]
  • [Cites] Blood. 2009 Apr 23;113(17):3931-7 [19029440.001]
  • [Cites] Arch Pathol Lab Med. 2009 May;133(5):692-8 [19415943.001]
  • [Cites] Clin Microbiol Infect. 2009 Oct;15 Suppl 5:98-102 [19754767.001]
  • [Cites] Head Neck. 2010 Feb;32(2):268-73 [19360743.001]
  • [Cites] Pathol Oncol Res. 2010 Mar;16(1):133-7 [19590983.001]
  • [Cites] Oncology (Williston Park). 2010 Apr 15;24(4):352-8 [20464847.001]
  • [Cites] Oncology (Williston Park). 2010 Apr 15;24(4):359, 362 [20464848.001]
  • [Cites] Surv Ophthalmol. 2010 Sep-Oct;55(5):429-44 [20638092.001]
  • [Cites] J Natl Med Assoc. 2001 May;93(5):178-84 [11405595.001]
  • [Cites] Ear Nose Throat J. 2001 Oct;80(10):738-40, 742-3 [11605572.001]
  • [Cites] Br J Oral Maxillofac Surg. 1988 Dec;26(6):486-90 [3203090.001]
  • [Cites] Genitourin Med. 1997 Jun;73(3):225 [9306911.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005 May;99(5):594-7 [15829883.001]
  • [Cites] J Oral Maxillofac Surg. 2000 Nov;58(11):1323-7 [11078150.001]
  • (PMID = 22707606.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3063295
  •  go-up   go-down


2. Kim TH, Kim JS, Suh YG, Cho J, Yang WI, Suh CO: The Roles of Radiotherapy and Chemotherapy in the Era of Multimodal Treatment for Early-Stage Nasal-Type Extranodal Natural Killer/T-Cell Lymphoma. Yonsei Med J; 2016 Jul;57(4):846-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Roles of Radiotherapy and Chemotherapy in the Era of Multimodal Treatment for Early-Stage Nasal-Type Extranodal Natural Killer/T-Cell Lymphoma.
  • PURPOSE: To evaluate radiotherapy (RT) and chemotherapy (CT) treatments of early-stage extranodal natural killer/T-cell lymphoma (ENKTL).
  • [MeSH-major] Chemoradiotherapy. Lymphoma, Extranodal NK-T-Cell / drug therapy. Lymphoma, Extranodal NK-T-Cell / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Male. Middle Aged. Retrospective Studies. Survival Rate. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27189276.001).
  • [ISSN] 1976-2437
  • [Journal-full-title] Yonsei medical journal
  • [ISO-abbreviation] Yonsei Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC4951459
  • [Keywords] NOTNLM ; Lymphoma / radiotherapy / recurrencec
  •  go-up   go-down


3. Deng D, Wang Y, Liu W, Qian Y: Oral and maxillofacial non-Hodgkin lymphomas: Case report with review of literature. Medicine (Baltimore); 2017 Sep;96(35):e7890
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the Chinese population (including the Taiwanese), head-neck NHLs are often seen with the tonsils, nasal cavity, nasal sinus, and the nasopharynx.
  • PATIENT CONCERNS: Four cases, including 3 males and 1 female aged between 43 and 70 years old with oral lesions (ulcerations and/or masses) and accompanying cervical lymphadenopathies and/or skin erythemas presented to the Department of Oral and Maxillofacial Surgery, the First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China from January 2010 to January 2015.
  • DIAGNOSES: The diagnoses of non-Hodgkin lymphomas were made by pathology, including nasal type extranodal NK/T-cell lymphoma, mycosis fungoides, subcutaneous panniculitis-like T-cell lymphoma, and extranodal marginal B-cell lymphoma of mucosa-associated lymphatic tissue.
  • [MeSH-major] Facial Neoplasms / physiopathology. Lymphoma, Non-Hodgkin / physiopathology. Mouth Neoplasms / physiopathology
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Male. Middle Aged. Time Factors

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ecancermedicalscience. 2016 Aug 17;10:665 [27594910.001]
  • [Cites] Pol Przegl Chir. 2012 Mar;84(3):113-8 [22659353.001]
  • [Cites] Neuroimaging Clin N Am. 2003 Aug;13(3):371-92 [14631680.001]
  • [Cites] Kaohsiung J Med Sci. 2012 Aug;28(8):435-41 [22892165.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2017 Jan 1;97(1):50-59 [27816363.001]
  • [Cites] Int J Oral Maxillofac Surg. 2010 Sep;39(9):869-72 [20538427.001]
  • [Cites] J Laryngol Otol. 2013 Jul;127(7):699-704 [23738972.001]
  • [Cites] Eur Ann Otorhinolaryngol Head Neck Dis. 2015 Apr;132(2):71-5 [25553969.001]
  • [Cites] Acta Otolaryngol. 2012 Nov;132(11):1224-31 [23025415.001]
  • [Cites] Oral Oncol. 2001 Jan;37(1):36-41 [11120481.001]
  • [Cites] Eur Ann Otorhinolaryngol Head Neck Dis. 2015 Nov;132(5):271-4 [26363601.001]
  • [Cites] Br J Radiol. 2004 Feb;77(914):111-5 [15010382.001]
  • [Cites] Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2009 Oct;23(19):878-80 [20120872.001]
  • [Cites] Ann Hematol. 2017 Apr;96(4):627-637 [28130574.001]
  • [Cites] Arch Dermatol. 2010 Jun;146(6):607-13 [20566923.001]
  • [Cites] Laryngoscope. 2002 Jun;112(6):1079-83 [12160277.001]
  • [Cites] Tumori. 2005 Nov-Dec;91(6):456-62 [16457141.001]
  • [Cites] Int J Med Sci. 2015 Jan 07;12(2):141-5 [25589890.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2004 May;16(3):186-92 [15191005.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2017 May;31(5):808-814 [27515575.001]
  • [Cites] Rom J Morphol Embryol. 2015;56(2):499-504 [26193219.001]
  • (PMID = 28858104.001).
  • [ISSN] 1536-5964
  • [Journal-full-title] Medicine
  • [ISO-abbreviation] Medicine (Baltimore)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Venkatakrishnan K, Kim TM, Lin CC, Thye LS, Chng WJ, Ma B, Chen MH, Zhou X, Liu H, Kelly V, Kim WS: Phase 1 study of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in East Asian cancer patients: pharmacokinetics and recommended phase 2 dose. Invest New Drugs; 2015 Aug;33(4):942-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One patient with extranodal T-/NK-cell lymphoma (nasal type) achieved a partial response and 18 (51 %) had stable disease.
  • [MeSH-minor] Adult. Aged. Asian Continental Ancestry Group. Female. Humans. Male. Maximum Tolerated Dose. Middle Aged. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Pharmacol Ther. 2013 Aug;94(2):195-8 [23872835.001]
  • [Cites] Int J Cancer. 2012 Dec 1;131(11):2693-703 [22488249.001]
  • [Cites] Blood. 2010 Jun 24;115(25):5202-13 [20382844.001]
  • [Cites] Pediatr Blood Cancer. 2010 Jul 15;55(1):26-34 [20108338.001]
  • [Cites] Int J Cancer. 2009 Jun 1;124(11):2607-15 [19230025.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3187-205 [16682719.001]
  • [Cites] Head Neck. 2009 May;31(5):625-34 [19107951.001]
  • [Cites] Oncogene. 2006 Nov 16;25(54):7148-58 [16715125.001]
  • [Cites] J Clin Oncol. 2007 Feb 10;25(5):579-86 [17242396.001]
  • [Cites] Oncol Rep. 2007 May;17(5):1083-8 [17390048.001]
  • [Cites] J Clin Oncol. 2014 Jan 1;32(1):44-50 [24043741.001]
  • [Cites] Lancet Oncol. 2012 Aug;13(8):790-801 [22658655.001]
  • [Cites] Clin Cancer Res. 2011 Dec 15;17(24):7614-24 [22016509.001]
  • [Cites] Clin Cancer Res. 2012 Sep 1;18(17):4764-74 [22753585.001]
  • [Cites] Mol Cancer Res. 2007 Jan;5(1):1-10 [17259342.001]
  • [Cites] J Hematop. 2009 Mar;2(1):2-8 [19669217.001]
  • [Cites] Lancet Oncol. 2015 Apr;16(4):395-405 [25728526.001]
  • [Cites] Mol Cancer Res. 2010 Mar;8(3):373-84 [20197380.001]
  • [Cites] Clin Pharmacol Ther. 2010 Mar;87(3):362-6 [20107436.001]
  • [Cites] Leuk Lymphoma. 2008 Mar;49(3):559-69 [18297535.001]
  • [Cites] Cancer Sci. 2010 May;101(5):1204-11 [20180813.001]
  • [Cites] Cancer. 2008 Apr 15;112(8):1688-98 [18311783.001]
  • [Cites] Gynecol Oncol. 2012 Oct;127(1):63-9 [22772063.001]
  • [Cites] J Cell Sci. 2007 Sep 1;120(Pt 17):2987-96 [17715155.001]
  • [Cites] Leuk Res. 2013 Apr;37(4):434-9 [23153524.001]
  • [Cites] Clin Pharmacokinet. 2013 Dec;52(12):1085-100 [23818090.001]
  • [Cites] Blood. 2009 Sep 24;114(13):2699-708 [19652203.001]
  • [Cites] Eur J Cancer. 2009 Jan;45(2):228-47 [19097774.001]
  • [Cites] J Cell Mol Med. 2011 Oct;15(10):2057-70 [21091633.001]
  • [Cites] Invest New Drugs. 2014 Jun;32(3):489-99 [24352795.001]
  • [Cites] Invest New Drugs. 2014 Dec;32(6):1181-7 [24879333.001]
  • [Cites] Clin Cancer Res. 2012 Sep 1;18(17):4775-84 [22767670.001]
  • [Cites] J Biol Chem. 2008 Nov 14;283(46):31785-90 [18801727.001]
  • [Cites] J Clin Pharmacol. 2015 Mar;55(3):336-47 [25302940.001]
  • [Cites] EMBO J. 1998 Jun 1;17(11):3052-65 [9606188.001]
  • [Cites] Clin Cancer Res. 2006 Dec 1;12(23):6869-75 [17145803.001]
  • [Cites] Cancer. 2013 Feb 15;119(4):904-14 [22972611.001]
  • [Cites] Cancer Chemother Pharmacol. 2011 Nov;68(5):1291-304 [21448591.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Dec;12(12):1518-22 [14693746.001]
  • [Cites] Cancer Biol Ther. 2008 Sep;7(9):1388-97 [18708766.001]
  • [Cites] Nat Rev Cancer. 2005 Jan;5(1):42-50 [15630414.001]
  • [Cites] J Biol Chem. 2003 Dec 19;278(51):51786-95 [14523000.001]
  • (PMID = 26084989.001).
  • [ISSN] 1573-0646
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT01512758
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Azepines; 0 / MLN 8237; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; EC 2.7.11.1 / Aurora Kinase A
  •  go-up   go-down


5. Takada H, Imadome KI, Shibayama H, Yoshimori M, Wang L, Saitoh Y, Uota S, Yamaoka S, Koyama T, Shimizu N, Yamamoto K, Fujiwara S, Miura O, Arai A: EBV induces persistent NF-κB activation and contributes to survival of EBV-positive neoplastic T- or NK-cells. PLoS One; 2017;12(3):e0174136
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EBV induces persistent NF-κB activation and contributes to survival of EBV-positive neoplastic T- or NK-cells.
  • Epstein-Barr virus (EBV) has been detected in several T- and NK-cell neoplasms such as extranodal NK/T-cell lymphoma nasal type, aggressive NK-cell leukemia, EBV-positive peripheral T-cell lymphoma, systemic EBV-positive T-cell lymphoma of childhood, and chronic active EBV infection (CAEBV).
  • However, how this virus contributes to lymphomagenesis in T or NK cells remains largely unknown.
  • Here, we examined NF-κB activation in EBV-positive T or NK cell lines, SNT8, SNT15, SNT16, SNK6, and primary EBV-positive and clonally proliferating T/NK cells obtained from the peripheral blood of patients with CAEBV.
  • Western blotting, electrophoretic mobility shift assays, and immunofluorescent staining revealed persistent NF-κB activation in EBV-infected cell lines and primary cells from patients.
  • IMD-0354, a specific inhibitor of NF-κB that suppresses NF-κB activation in cell lines, inhibited cell survival and induced apoptosis.
  • These results indicate that EBV induces NF-κB-mediated survival signals in T and NK cells, and therefore, may contribute to the lymphomagenesis of these cells.
  • [MeSH-major] Epstein-Barr Virus Infections / complications. Epstein-Barr Virus Infections / immunology. Herpesvirus 4, Human / immunology. Killer Cells, Natural / virology. Lymphoma, T-Cell / virology. NF-kappa B / immunology. T-Lymphocytes / virology
  • [MeSH-minor] Adolescent. Adult. Cell Line, Tumor. Cell Survival. Chronic Disease. Female. Humans. Male. Middle Aged. Viral Matrix Proteins / immunology. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2012 Apr 15;18(8):2164-72 [22371452.001]
  • [Cites] J Clin Microbiol. 1999 Jan;37(1):132-6 [9854077.001]
  • [Cites] Br J Haematol. 2003 Jun;121(5):805-14 [12780797.001]
  • [Cites] J Clin Invest. 2001 Jan;107(1):3-6 [11134170.001]
  • [Cites] Am J Hematol. 2005 Sep;80(1):64-9 [16138335.001]
  • [Cites] J Pathol. 2011 Mar;223(4):496-510 [21294123.001]
  • [Cites] Nat Rev Immunol. 2009 Apr;9(4):271-85 [19319144.001]
  • [Cites] Pathol Int. 2008 Apr;58(4):209-17 [18324913.001]
  • [Cites] Blood. 2016 May 19;127(20):2375-90 [26980727.001]
  • [Cites] Blood. 2012 Jan 19;119(3):673-86 [22096243.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 6;101(1):141-6 [14691250.001]
  • [Cites] Biol Chem. 2008 Oct;389(10):1261-71 [18713013.001]
  • [Cites] J Pathol. 2010 Jun;221(2):164-74 [20235165.001]
  • [Cites] Int J Cancer. 1973 May;11(3):499-520 [4133943.001]
  • [Cites] PLoS One. 2014 Nov 19;9(11):e112564 [25409517.001]
  • [Cites] Int J Hematol. 2012 Nov;96(5):669-73 [22983646.001]
  • [Cites] Clin Exp Immunol. 2008 Mar;151(3):519-27 [18190605.001]
  • [Cites] Blood. 2010 Feb 11;115(6):1226-37 [19965620.001]
  • [Cites] Science. 1995 Sep 8;269(5229):1424-7 [7544915.001]
  • [Cites] J Virol. 2001 Jun;75(11):5059-68 [11333886.001]
  • [Cites] PLoS Pathog. 2011 Oct;7(10):e1002326 [22028658.001]
  • [Cites] Blood. 2006 Apr 15;107(8):3295-302 [16380446.001]
  • [Cites] Blood. 2008 May 15;111(10):5118-29 [18305221.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jun 24;100(13):7836-40 [12805559.001]
  • [Cites] Cancer Sci. 2012 Jan;103(1):100-6 [21951590.001]
  • [Cites] Nat Rev Cancer. 2002 Apr;2(4):301-10 [12001991.001]
  • [Cites] J Biol Chem. 1999 Oct 15;274(42):30154-62 [10514505.001]
  • [Cites] J Infect Dis. 2005 Oct 15;192(8):1340-8 [16170750.001]
  • [Cites] Blood. 2005 Mar 15;105(6):2324-31 [15561889.001]
  • [Cites] J Virol. 2004 Apr;78(8):4108-19 [15047827.001]
  • [ErratumIn] PLoS One. 2017 Aug 1;12 (8):e0182682 [28763513.001]
  • (PMID = 28346502.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / EBV-associated membrane antigen, Epstein-Barr virus; 0 / NF-kappa B; 0 / Viral Matrix Proteins
  •  go-up   go-down


6. Chen R, Lu M, Wang J, Zhang D, Lin H, Zhu H, Zhang W, Xiong L, Ma J, Mao Y, Zhu J, Xu J: Increased expression of Trop2 correlates with poor survival in extranodal NK/T cell lymphoma, nasal type. Virchows Arch; 2013 Nov;463(5):713-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased expression of Trop2 correlates with poor survival in extranodal NK/T cell lymphoma, nasal type.
  • Human trophoblastic cell surface antigen 2 (Trop2) has been suggested to play an important role in the development of solid tumors.
  • However, the expression of Trop2 in extranodal NK/T cell lymphoma, nasal type (ENKTL) and the relationship with the clinical characteristics of this disease remain poorly understood.
  • [MeSH-major] Antigens, Neoplasm / biosynthesis. Biomarkers, Tumor / analysis. Cell Adhesion Molecules / metabolism. Lymphoma, Extranodal NK-T-Cell / metabolism. Nose Neoplasms / metabolism
  • [MeSH-minor] Adult. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Prognosis

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer. 2010 Mar;46(5):944-53 [20060709.001]
  • [Cites] Diagn Pathol. 2012 Dec 13;7:178 [23237707.001]
  • [Cites] J Exp Clin Cancer Res. 2012 Dec 12;31:101 [23231769.001]
  • [Cites] Exp Mol Pathol. 2013 Feb;94(1):73-8 [23031786.001]
  • [Cites] Head Neck. 2013 Oct;35(10):1373-8 [22987366.001]
  • [Cites] Int J Cancer. 1998 Jan 19;75(2):324-30 [9462726.001]
  • [Cites] Clin Cancer Res. 2005 Jun 15;11(12):4357-64 [15958618.001]
  • [Cites] Br J Cancer. 2008 Oct 21;99(8):1290-5 [18813308.001]
  • [Cites] J Clin Pathol. 2007 Jun;60(6):656-60 [16775124.001]
  • [Cites] Int J Cancer. 2002 Oct 1;101(4):353-9 [12209960.001]
  • [Cites] Am J Clin Pathol. 2012 Sep;138(3):435-47 [22912362.001]
  • [Cites] Mol Cancer Ther. 2008 Feb;7(2):280-5 [18281513.001]
  • [Cites] Mod Pathol. 2008 Feb;21(2):186-91 [18084248.001]
  • [Cites] Lab Invest. 2004 Mar;84(3):320-31 [14767486.001]
  • [Cites] Oral Oncol. 2007 Jan;43(1):4-14 [17064952.001]
  • [Cites] Int J Cancer. 2004 Dec 20;112(6):1029-35 [15386348.001]
  • [Cites] Virchows Arch. 2007 Mar;450(3):355-8 [17252228.001]
  • [Cites] Virchows Arch. 2013 Apr;462(4):399-407 [23494713.001]
  • [Cites] J Clin Pathol. 2009 Feb;62(2):152-8 [18930986.001]
  • [Cites] Clin Cancer Res. 2006 May 15;12(10):3057-63 [16707602.001]
  • [Cites] Int J Cancer. 1998 May 29;76(5):671-6 [9610724.001]
  • [Cites] Int J Mol Sci. 2012;13(2):2208-18 [22408448.001]
  • [Cites] Am J Clin Pathol. 2007 Oct;128(4):579-84 [17875508.001]
  • [Cites] Nature. 2004 May 27;429(6990):457-63 [15164071.001]
  • [Cites] Int J Hematol. 2008 Mar;87(2):110-7 [18256789.001]
  • [Cites] Proc Natl Acad Sci U S A. 1981 Aug;78(8):5147-50 [7029529.001]
  • [Cites] Anticancer Res. 2010 Jul;30(7):2497-503 [20682974.001]
  • [Cites] Int J Colorectal Dis. 2009 Aug;24(8):875-84 [19421758.001]
  • (PMID = 23979406.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Cell Adhesion Molecules; 0 / TACSTD2 protein, human
  •  go-up   go-down


7. Li Y, Wei J, Mao X, Gao Q, Liu L, Cheng P, Liu L, Zhang X, Zhang K, Wang J, Zhu L, Zhou J, Zhang Y, Meng L, Sun H, Li D, Huang M, Huang W, Deng J, Zhang D: Flow Cytometric Immunophenotyping Is Sensitive for the Early Diagnosis of De Novo Aggressive Natural Killer Cell Leukemia (ANKL): A Multicenter Retrospective Analysis. PLoS One; 2016;11(8):e0158827
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Flow Cytometric Immunophenotyping Is Sensitive for the Early Diagnosis of De Novo Aggressive Natural Killer Cell Leukemia (ANKL): A Multicenter Retrospective Analysis.
  • Aggressive natural killer cell leukemia (ANKL) is a fatal hematological neoplasm characterized by a fulminating clinical course and extremely high mortality.
  • Current diagnosis of this disease is not effective during the early stages and it is easily misdiagnosed as other NK cell disorders.
  • Patients with extranodal NK/T cell lymphoma, nasal type (ENKTL) and chronic lymphoproliferative disorder of NK cell (CLPD-NK), who were diagnosed during the same time period were used for comparisons.
  • Abnormal NK cells in ANKL were found to have a distinctiveCD56bright/CD16dim immunophenotype and markedly increased Ki-67 expression, whereas CD57 negativity and reduced expression of killer immunoglobulin-like receptor (KIR), CD161, CD7, CD8 and perforin were exhibited compared with other NK cell proliferative disorders (p<0.05).
  • [MeSH-major] Bone Marrow / pathology. Flow Cytometry / methods. Immunophenotyping / methods. Killer Cells, Natural / pathology. Leukemia, Large Granular Lymphocytic / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Cytogenetic Analysis. Diagnosis, Differential. Early Detection of Cancer. Female. Humans. Karyotype. Male. Middle Aged. Prognosis. Retrospective Studies. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leuk Res. 2007 Sep;31(9):1237-45 [17123604.001]
  • [Cites] J Clin Exp Hematop. 2012;52(2):101-6 [23037625.001]
  • [Cites] Blood. 2010 Nov 11;116(19):3853-64 [20696944.001]
  • [Cites] Orphanet J Rare Dis. 2013 Jul 01;8:95 [23816348.001]
  • [Cites] Int Arch Allergy Immunol. 2014;164(4):253-64 [25323661.001]
  • [Cites] Ann Med. 2014 May;46(3):114-22 [24512550.001]
  • [Cites] Leukemia. 2005 Jul;19(7):1169-74 [15902300.001]
  • [Cites] Ann Oncol. 2010 May;21(5):1032-40 [19850638.001]
  • [Cites] Blood. 1986 Apr;67(4):925-30 [3955237.001]
  • [Cites] Am J Clin Pathol. 2007 Jun;127(6):881-6 [17509985.001]
  • [Cites] Ann Hematol. 2013 Jan;92(1):89-96 [22992980.001]
  • [Cites] Am J Hematol. 2006 Aug;81(8):576-81 [16823820.001]
  • [Cites] Blood. 2004 Jul 1;104(1):243-9 [15031209.001]
  • [Cites] Immunology. 2009 Apr;126(4):458-65 [19278419.001]
  • [Cites] Blood Rev. 2014 May;28(3):87-94 [24679833.001]
  • [Cites] Transl Res. 2014 Jun;163(6):565-77 [24524877.001]
  • [Cites] Diagn Pathol. 2013 Mar 11;8:43 [23510456.001]
  • [Cites] Blood. 2010 Nov 11;116(19):3865-74 [20733159.001]
  • [Cites] Blood. 1997 Jun 15;89(12):4501-13 [9192774.001]
  • [Cites] Front Immunol. 2014 Feb 26;5:72 [24616720.001]
  • [Cites] N Engl J Med. 2012 May 17;366(20):1905-13 [22591296.001]
  • [Cites] Blood. 2014 Oct 16;124(16):2533-43 [25205117.001]
  • [Cites] Clin Infect Dis. 2006 Nov 1;43(9):1143-51 [17029132.001]
  • [Cites] Haematologica. 2002 Dec;87(12):1343-5 [12495907.001]
  • [Cites] Clin Lymphoma Myeloma. 2006 Mar;6(5):417-9 [16640822.001]
  • [Cites] Clin Nucl Med. 2011 Oct;36(10 ):932-3 [21892052.001]
  • [Cites] Cancer Sci. 2012 Jun;103(6):1079-83 [22360679.001]
  • [Cites] J Immunol. 2014 Oct 1;193(7):3344-54 [25172483.001]
  • [Cites] Eur J Haematol. 2008 Aug;81(2):107-11 [18462253.001]
  • [Cites] Br J Haematol. 1990 May;75(1):49-59 [2375924.001]
  • [Cites] J Clin Exp Hematop. 2011;51(1):21-8 [21628857.001]
  • [Cites] Blood. 2002 Aug 15;100(4):1449-53 [12149230.001]
  • [Cites] Acta Haematol. 2008;120(4):199-206 [19153474.001]
  • [Cites] Front Immunol. 2014 Mar 31;5:133 [24744756.001]
  • [Cites] J Immunol. 2004 Feb 1;172(3):1455-62 [14734722.001]
  • [Cites] Blood Rev. 2006 May;20(3):123-37 [16364519.001]
  • [Cites] Int J Hematol. 2007 Jan;85(1):18-25 [17261497.001]
  • [Cites] Intern Med. 2010;49(17 ):1907-10 [20823655.001]
  • [Cites] Front Immunol. 2013 Dec 30;4:499 [24416035.001]
  • [Cites] Leukemia. 2004 Apr;18(4):763-70 [14961041.001]
  • [Cites] Ann Oncol. 2005 Feb;16(2):206-14 [15668271.001]
  • [Cites] Eur J Immunol. 2004 Oct;34(10):2930-40 [15368309.001]
  • [Cites] Korean J Lab Med. 2009 Dec;29(6):491-6 [20046078.001]
  • [Cites] Leuk Lymphoma. 2015 Jan;56(1):103-12 [24669939.001]
  • [Cites] Am J Med Sci. 2013 Jul;346(1):56-63 [23241562.001]
  • [Cites] Int J Clin Exp Pathol. 2014 May 15;7(6):3423-31 [25031771.001]
  • [Cites] J Immunol. 2007 Apr 15;178(8):4947-55 [17404276.001]
  • [Cites] Blood. 2010 Feb 11;115(6):1166-74 [19903900.001]
  • [Cites] Blood. 2013 Jun 6;121(23):4703-7 [23637128.001]
  • [Cites] Leuk Lymphoma. 2004 Dec;45(12):2427-38 [15621755.001]
  • [Cites] Leukemia. 2007 May;21(5):1060-9 [17361229.001]
  • [Cites] Blood. 2013 Apr 4;121(14):2678-88 [23325834.001]
  • [Cites] Hematology. 2005 Jun;10(3):237-45 [16019472.001]
  • (PMID = 27483437.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC4970793
  •  go-up   go-down


8. Chauchet A, Michallet AS, Berger F, Bedgedjian I, Deconinck E, Sebban C, Antal D, Orfeuvre H, Corront B, Petrella T, Hacini M, Bouteloup M, Salles G, Coiffier B: Complete remission after first-line radio-chemotherapy as predictor of survival in extranodal NK/T cell lymphoma. J Hematol Oncol; 2012;5:27
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete remission after first-line radio-chemotherapy as predictor of survival in extranodal NK/T cell lymphoma.
  • BACKGROUND: Extranodal nasal-type NK/T-cell lymphoma is a rare and severe disease.
  • Considering the rarity of this lymphoma in Europe, we conducted a multicentric retrospective study on nasal-type NK/T cell lymphoma to determine the optimal induction strategy and identify prognostic factors.
  • METHODS: Thirty-six adult patients with nasal-type NK/T-cell lymphoma were recruited and assessed.
  • In total, 80 % of patients were classified as having upper aerodigestive tract NK/T-cell lymphoma (UNKTL) and 20 % extra-upper aerodigestive tract NK/T-cell lymphoma (EUNKTL).
  • [MeSH-major] Chemoradiotherapy. Lymphoma, Extranodal NK-T-Cell / mortality. Lymphoma, Extranodal NK-T-Cell / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Predictive Value of Tests. Remission Induction. Retrospective Studies. Survival Rate. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Pathol. 2001 Feb;115(2):266-70 [11211616.001]
  • [Cites] Clin Lab Haematol. 2000 Aug;22(4):215-20 [11012633.001]
  • [Cites] Eur J Cancer. 2002 Jan;38(1):75-81 [11750843.001]
  • [Cites] Ann Oncol. 2002 Jan;13(1):140-9 [11863096.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Sep 1;54(1):182-90 [12182990.001]
  • [Cites] Semin Hematol. 2003 Jul;40(3):175-84 [12876666.001]
  • [Cites] Int J Hematol. 2003 Aug;78(2):163-7 [12953813.001]
  • [Cites] Int J Hematol. 2003 Oct;78(3):248-50 [14604284.001]
  • [Cites] Blood. 2004 Jan 1;103(1):216-21 [12933580.001]
  • [Cites] Cancer. 2004 Jan 15;100(2):366-75 [14716773.001]
  • [Cites] Ann Oncol. 2004 Apr;15(4):618-25 [15033670.001]
  • [Cites] Blood. 2004 Apr 1;103(7):2474-9 [14645001.001]
  • [Cites] Mod Pathol. 2004 Sep;17(9):1097-107 [15195107.001]
  • [Cites] Int J Surg Pathol. 2004 Oct;12(4):375-87 [15494863.001]
  • [Cites] Cancer. 1985 Aug 15;56(4):814-9 [4016673.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14):987-94 [8141877.001]
  • [Cites] Br J Haematol. 1997 Jun;97(4):821-9 [9217183.001]
  • [Cites] Cancer. 1997 Aug 1;80(3):477-88 [9241082.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):70-7 [9440725.001]
  • [Cites] Cancer. 1998 Aug 1;83(3):449-56 [9690537.001]
  • [Cites] Hum Pathol. 1999 Jul;30(7):849-55 [10414505.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Feb 1;61(2):476-9 [15667970.001]
  • [Cites] Jpn J Clin Oncol. 2005 Jan;35(1):1-5 [15681596.001]
  • [Cites] Br J Cancer. 2005 Apr 11;92(7):1226-30 [15798768.001]
  • [Cites] Eur J Cancer. 2005 Jul;41(10):1402-8 [15963893.001]
  • [Cites] Hematology. 2005 Jun;10(3):237-45 [16019472.001]
  • [Cites] J Clin Oncol. 2006 Jan 1;24(1):181-9 [16382127.001]
  • [Cites] Cancer. 2006 Feb 1;106(3):609-15 [16369986.001]
  • [Cites] J Clin Oncol. 2006 Feb 1;24(4):612-8 [16380410.001]
  • [Cites] Hematol Oncol. 2006 Mar;24(1):28-32 [16323259.001]
  • [Cites] Ann Oncol. 2006 May;17(5):794-800 [16497823.001]
  • [Cites] Blood. 2007 Mar 1;109(5):2183-9 [17077322.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2007 Mar;15(1):38-44 [17536305.001]
  • [Cites] Hematol Oncol Clin North Am. 2007 Oct;21(5):841-54 [17908623.001]
  • [Cites] Br J Haematol. 2007 Nov;139(4):532-44 [17916099.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Jan 1;70(1):166-74 [17919841.001]
  • [Cites] Eur J Haematol. 2008 Jan;80(1):55-60 [18028433.001]
  • [Cites] Ann Oncol. 2008 Aug;19(8):1477-84 [18385201.001]
  • [Cites] J Clin Oncol. 2008 Sep 1;26(25):4124-30 [18626005.001]
  • [Cites] Ann Oncol. 2009 Jan;20(1):110-6 [18701429.001]
  • [Cites] Clin Cancer Res. 2009 Apr 15;15(8):2905-12 [19318493.001]
  • [Cites] Blood. 2009 Apr 23;113(17):3931-7 [19029440.001]
  • [Cites] Ann Hematol. 2009 Jul;88(7):647-52 [19107482.001]
  • [Cites] Lancet Oncol. 2009 Nov;10(11):1093-101 [19880063.001]
  • [Cites] J Clin Oncol. 2009 Nov 20;27(33):5594-600 [19805668.001]
  • [Cites] J Clin Oncol. 2009 Dec 10;27(35):6027-32 [19884539.001]
  • [Cites] Ann Oncol. 2010 May;21(5):1032-40 [19850638.001]
  • [Cites] Blood. 2011 Feb 10;117(6):1834-9 [21123825.001]
  • [Cites] Br J Haematol. 2011 May;153(4):451-85 [21480860.001]
  • [Cites] J Clin Oncol. 2011 Nov 20;29(33):4410-6 [21990393.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(1):54-63 [10623693.001]
  • [Cites] Ann Oncol. 2001 Mar;12(3):349-52 [11332147.001]
  • (PMID = 22682004.001).
  • [ISSN] 1756-8722
  • [Journal-full-title] Journal of hematology & oncology
  • [ISO-abbreviation] J Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3416641
  •  go-up   go-down


9. Li YJ, Li ZM, Xia Y, Huang JJ, Huang HQ, Xia ZJ, Lin TY, Li S, Cai XY, Wu-Xiao ZJ, Jiang WQ: Serum C-reactive protein (CRP) as a simple and independent prognostic factor in extranodal natural killer/T-cell lymphoma, nasal type. PLoS One; 2013;8(5):e64158
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum C-reactive protein (CRP) as a simple and independent prognostic factor in extranodal natural killer/T-cell lymphoma, nasal type.
  • The prognostic significance of CRP for lymphoma has not been fully examined.
  • We evaluated the prognostic role of baseline serum CRP levels in patients with extranodal natural killer (NK)/T-cell lymphoma (ENKTL).
  • [MeSH-major] C-Reactive Protein / metabolism. Lymphoma, Extranodal NK-T-Cell / blood
  • [MeSH-minor] Adolescent. Adult. Aged. Disease-Free Survival. Female. Humans. Male. Middle Aged. Multivariate Analysis. Prognosis. Republic of Korea. Risk Factors. Survival Analysis. Young Adult

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Immunol. 2005 Nov;117(2):104-11 [16214080.001]
  • [Cites] J Am Coll Cardiol. 2005 Aug 2;46(3):464-9 [16053959.001]
  • [Cites] Br J Cancer. 2006 Mar 13;94(5):637-41 [16479253.001]
  • [Cites] Int J Urol. 2006 Nov;13(11):1365-70 [17083384.001]
  • [Cites] Eur J Haematol. 2007 Aug;79(2):150-4 [17635239.001]
  • [Cites] Ann Oncol. 2007 Aug;18(8):1382-7 [17693651.001]
  • [Cites] Cancer Cell. 2007 Sep;12(3):252-65 [17785206.001]
  • [Cites] Clin Chem. 2008 Feb;54(2):335-42 [18156284.001]
  • [Cites] Nature. 2008 Jul 24;454(7203):436-44 [18650914.001]
  • [Cites] J Clin Oncol. 2008 Sep 1;26(25):4124-30 [18626005.001]
  • [Cites] Blood. 2009 Apr 23;113(17):3931-7 [19029440.001]
  • [Cites] J Clin Oncol. 2009 Jul 20;27(21):3437-44 [19470939.001]
  • [Cites] Cell. 2010 Mar 19;140(6):883-99 [20303878.001]
  • [Cites] J Thorac Oncol. 2010 Jul;5(7):988-92 [20453690.001]
  • [Cites] Eur Heart J. 2010 Jul;31(13):1624-32 [20423919.001]
  • [Cites] Ann Oncol. 2011 Jan;22(1):149-55 [20595450.001]
  • [Cites] Br J Cancer. 2011 Feb 15;104(4):726-34 [21266974.001]
  • [Cites] World J Surg Oncol. 2011;9:18 [21294915.001]
  • [Cites] Crit Rev Clin Lab Sci. 2011 Jul-Aug;48(4):155-70 [22035340.001]
  • [Cites] Eur J Cancer. 2011 Nov;47(17):2633-41 [21724383.001]
  • [Cites] Tumour Biol. 2012 Aug;33(4):1039-44 [22328138.001]
  • [Cites] Clin Chim Acta. 2012 Oct 9;413(19-20):1583-90 [22609487.001]
  • [Cites] Cancer Treat Rev. 2013 Feb;39(1):89-96 [22858249.001]
  • [Cites] PLoS Genet. 2013;9(2):e1003251 [23408900.001]
  • [Cites] J Clin Lab Anal. 2013 May;27(3):207-10 [23426911.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] Am J Surg. 2001 Aug;182(2):197-201 [11574097.001]
  • [Cites] Br J Surg. 2003 Feb;90(2):215-9 [12555298.001]
  • [Cites] Am J Cardiol. 2003 Feb 1;91(3):368-70 [12565104.001]
  • [Cites] Diabetes Metab. 2003 Apr;29(2 Pt 1):133-8 [12746633.001]
  • [Cites] Med Pediatr Oncol. 2003 Jul;41(1):21-5 [12764738.001]
  • [Cites] Blood. 2004 Jan 1;103(1):216-21 [12933580.001]
  • [Cites] Ann Oncol. 2004 Apr;15(4):618-25 [15033670.001]
  • [Cites] Leuk Lymphoma. 1998 Oct;31(3-4):351-7 [9869199.001]
  • [Cites] Cancer. 2005 May 1;103(9):1856-64 [15779015.001]
  • [Cites] Eur J Cancer. 2005 Jul;41(10):1402-8 [15963893.001]
  • [Cites] J Clin Oncol. 2006 Feb 1;24(4):612-8 [16380410.001]
  • (PMID = 23724031.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 9007-41-4 / C-Reactive Protein
  • [Other-IDs] NLM/ PMC3665788
  •  go-up   go-down


10. Liang L, Nong L, Zhang S, Zhao J, Ti H, Dong Y, Zhang B, Li T: The downregulation of PRDM1/Blimp-1 is associated with aberrant expression of miR-223 in extranodal NK/T-cell lymphoma, nasal type. J Exp Clin Cancer Res; 2014;33:7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The downregulation of PRDM1/Blimp-1 is associated with aberrant expression of miR-223 in extranodal NK/T-cell lymphoma, nasal type.
  • BACKGROUND: The mechanism for inactivation of positive regulatory domain containing I (PRDM1), a newly identified tumour suppressor gene in extranodal NK/T-cell lymphoma, nasal type (EN-NK/T-NT) has not been well defined.
  • The aim of the present study was to investigate the expression of PRDM1 in EN-NK/T-NT and analyse its downregulation by miRNAs.
  • METHODS: PRDM1 and miRNA expression were evaluated in EN-NK/T-NT samples by immunohistochemical analysis, qRT-PCR, and in situ hybridisation.
  • In addition, the effect of miR-223 on PRDM1 expression was assessed in NK/T lymphoma cell lines by transfecting a miR-223 mimic or inhibitor to increase or decrease the effective expression of miR-223.
  • Overall survival and failure-free survival in EN-NK/T-NT patients were analysed using Kaplan-Meier single-factor analysis and the log-rank test.
  • RESULTS: Investigation of the downregulation of PRDM1 in EN-NK/T-NT cases revealed that PRDM1-positive staining might be a favourable predictor of overall survival and failure-free survival in EN-NK/T-NT patients.
  • However, the negative staining of PRDM1 usually presented transcripts, suggesting a possible post-transcriptional regulation. miR-223 and its putative target gene, PRDM1, exhibited opposite patterns of expression in EN-NK/T-NT tissues and cell lines.
  • The ectopic expression of miR-223 led to the downregulation of the PRDM1 protein in the NK/T-cell lymphoma cell line, whereas a decrease in miR-223 restored the level of PRDM1 protein.
  • CONCLUSIONS: Our findings reveal that the downregulation of the tumour suppressor PRDM1 in EN-NK/T-NT samples is mediated by miR-223 and that PRDM1-positive staining might have prognostic value for evaluating the clinical outcome of EN-NK/T-NT patients.
  • [MeSH-major] Lymphoma, Extranodal NK-T-Cell / metabolism. MicroRNAs / genetics. Nose Neoplasms / metabolism. Repressor Proteins / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Base Sequence. Binding Sites. Cell Line, Tumor. Child. Disease-Free Survival. Down-Regulation. Female. Gene Expression. Gene Expression Regulation, Neoplastic. Humans. Kaplan-Meier Estimate. Male. Middle Aged. RNA Interference. Retrospective Studies. Young Adult

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Immunity. 2000 Aug;13(2):199-212 [10981963.001]
  • [Cites] J Exp Clin Cancer Res. 2012;31:38 [22546315.001]
  • [Cites] Leuk Lymphoma. 2003 Dec;44(12):2077-82 [14959850.001]
  • [Cites] J Immunol. 1985 Mar;134(3):1623-30 [2578514.001]
  • [Cites] Leukemia. 1994 Apr;8(4):652-8 [8152260.001]
  • [Cites] Exp Hematol. 1996 Feb;24(3):406-15 [8599969.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Nov;44(3):247-55 [16049916.001]
  • [Cites] Cell. 2005 Dec 2;123(5):819-31 [16325577.001]
  • [Cites] J Exp Med. 2006 Feb 20;203(2):311-7 [16492805.001]
  • [Cites] Nat Rev Cancer. 2006 Apr;6(4):259-69 [16557279.001]
  • [Cites] Haematologica. 2006 Apr;91(4):467-74 [16585013.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):19971-6 [18056805.001]
  • [Cites] J Biol Chem. 2008 Jan 11;283(2):951-62 [17977828.001]
  • [Cites] Nature. 2008 Feb 28;451(7182):1125-9 [18278031.001]
  • [Cites] Int J Hematol. 2008 Mar;87(2):110-7 [18256789.001]
  • [Cites] Am J Pathol. 2008 Jul;173(1):242-52 [18583325.001]
  • [Cites] Blood. 2009 Jan 8;113(2):396-402 [18941111.001]
  • [Cites] Blood. 2009 May 21;113(21):5237-45 [19144983.001]
  • [Cites] Leukemia. 2009 Jun;23(6):1139-51 [19194464.001]
  • [Cites] Leukemia. 2009 Sep;23(9):1667-78 [19421230.001]
  • [Cites] Blood. 2009 Oct 8;114(15):3265-75 [19641183.001]
  • [Cites] Blood. 2010 Feb 11;115(6):1226-37 [19965620.001]
  • [Cites] Blood. 2010 Mar 4;115(9):1768-78 [20029046.001]
  • [Cites] Mol Cancer Res. 2010 Jun;8(6):907-18 [20530581.001]
  • [Cites] Haematologica. 2010 Jul;95(7):1114-21 [20418243.001]
  • [Cites] Am J Pathol. 2010 Sep;177(3):1470-9 [20651244.001]
  • [Cites] Mod Pathol. 2010 Nov;23(11):1507-17 [20802470.001]
  • [Cites] Cancer Cell. 2010 Dec 14;18(6):568-79 [21156281.001]
  • [Cites] Cancer Cell. 2010 Dec 14;18(6):580-9 [21156282.001]
  • [Cites] Cell Prolif. 2011 Feb;44(1):59-66 [21199010.001]
  • [Cites] Blood. 2011 Feb 10;117(6):1869-79 [21131593.001]
  • [Cites] Blood. 2011 Jun 2;117(22):5907-17 [21411757.001]
  • [Cites] Hum Pathol. 2011 Sep;42(9):1319-28 [21329961.001]
  • [Cites] Blood. 2011 Sep 22;118(12):3195-204 [21690554.001]
  • [Cites] Blood. 2011 Nov 3;118(18):4919-29 [21921041.001]
  • [Cites] Proc Natl Acad Sci U S A. 2011 Dec 13;108(50):20119-24 [22143801.001]
  • [Cites] J Exp Clin Cancer Res. 2011;30:110 [22133358.001]
  • [Cites] Zhonghua Bing Li Xue Za Zhi. 2011 Sep;40(9):610-5 [22177245.001]
  • [Cites] PLoS One. 2012;7(8):e42193 [22870299.001]
  • [Cites] Am J Clin Pathol. 2012 Sep;138(3):435-47 [22912362.001]
  • [Cites] Cytometry. 2001 Apr 15;46(2):85-91 [11309817.001]
  • (PMID = 24438193.001).
  • [ISSN] 1756-9966
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / MIRN223 microRNA, human; 0 / MicroRNAs; 0 / Repressor Proteins; 138415-26-6 / PRDM1 protein, human
  • [Other-IDs] NLM/ PMC3898819
  •  go-up   go-down






Advertisement